Pfizer (PFE) : Ropes Wealth Advisors scooped up 5,212 additional shares in Pfizer during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 159,580 shares of Pfizer which is valued at $4.7 Million.Pfizer makes up approximately 2.33% of Ropes Wealth Advisors’s portfolio.
Other Hedge Funds, Including , Jupiter Asset Management Ltd reduced its stake in PFE by selling 57,734 shares or 5.75% during the fourth quarter. The Hedge Fund company now holds 946,713 shares of PFE which is valued at $27.9 Million. Pfizer makes up approx 1.07% of Jupiter Asset Management Ltd’s portfolio.Howland Capital Management boosted its stake in PFE during the Q4 period, The investment management firm added 7,556 additional shares and now holds a total of 81,946 shares of Pfizer which is valued at $2.4 Million. Pfizer makes up approx 0.24% of Howland Capital Management’s portfolio.Sns Financial Group boosted its stake in PFE during the Q4 period, The investment management firm added 5,192 additional shares and now holds a total of 62,206 shares of Pfizer which is valued at $1.8 Million. Pfizer makes up approx 0.74% of Sns Financial Group’s portfolio.
On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Many Wall Street Analysts have commented on Pfizer. Pfizer was Upgraded by Sun Trust Rbsn Humphrey to ” Neutral” on Nov 25, 2015.
Pfizer opened for trading at $29.45 and hit $30.12 on the upside on Monday, eventually ending the session at $30.07, with a gain of 2.11% or 0.62 points. The heightened volatility saw the trading volume jump to 3,52,22,287 shares. Company has a market cap of $185,957 M.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.